BWP
ACAD icon

Baldwin Wealth Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Baldwin Wealth Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$1.59K – 802
2022
Q4 		$1.59K Buy
+100
New +$1.56K ﹤0.01% 722

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baldwin Wealth Partners's ACAD Position: Q1 2023 in Review

Baldwin Wealth Partners sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 100 shares — an estimated $1.59K sold.

Baldwin Wealth Partners first reported a position in ACAD in Q4 2022 and held it in 1 quarter. The position peaked at $1.59K in Q4 2022. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

  • Baldwin Wealth Partners reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Baldwin Wealth Partners sold 100 Acadia Pharmaceuticals shares in Q1 2023, an estimated $1.59K.
  • Baldwin Wealth Partners first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Baldwin Wealth Partners's Acadia Pharmaceuticals position peaked at $1.59K in Q4 2022.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Baldwin Wealth Partners's 13F filing for Q1 2023, filed 21 Apr 2023.